If not meeting glycemic goals after 4 weeks, increase dose as tolerated every 4 weeks as follows: 1.5 mg SubQ once weekly, then 3 mg SubQ once weekly, then 4.5 mg SubQ once weekly
(5) DBS-ECoG dataset: 17 patients with PD who underwent STN-DBS surgery and DBS-evoked ECoG recording
Retatrutide vs tirzepatide is not a simple winner-takes-all question
La prise en charge effective est attendue au second semestre 2026
Beyond achieving weight loss, semaglutide contributes to enhanced health markers aligned with improved heart disease, stroke, and type 2 diabetes management, making it a comprehensive health advancement tool in Maine
Though semaglutides like Ozempic and Wegovy dominate the market in the U.S., Al-Aly and his team included all GLP-1 drugs in the study